Read full story for latest details. ...

Here is a recap of the top news items from this week on Wall Street: 1. The important September jobs number was released on Friday and as had been anticipated, was worse than expected. The data showed that the change in nonfarm payrolls for September was down 263,000, vs. the consensus of -175,000. The unemployment rate for the month came in at 9...

The Trading Radar highlights key earnings and economic announcements for tomorrow’s trading session: Before Market Opens: Earnings: RPM International (NYSE: RPM) - consensus EPS $0.44 Intraday or Not Specified: Economics: 10am ET ISM Services for Sept. - Street expects 50 After Market Closes: Earnings: Robbins & Myers (NYSE: RBN) - cons...

EnteroMedics Inc. (NASDAQ: ETRM) 72.6% LOWER; announced preliminary results from its EMPOWER Study. Based on an initial analysis, the study did not meet its primary and secondary efficacy endpoints. There were no therapy-related serious adverse events reported in the study. The EMPOWER Study is a randomized, double-blind, placebo-controlled pivotal...

UPGRADES: UBS upgrades Apple (Nasdaq: AAPL) from Neutral to Buy, citing higher iPhone expectations. The firm also raised its price target from $170 to $265. This new target represents the new “Street high”. Click here for more color. Oppenheimer upgrades Intel Corporation (Nasdaq: INTC) from Market Perform to Outperform with a $28 price...

On September 30, 2009, Beauty Systems Group LLC, a subsidiary of Sally Beauty Holdings (NYSE: SBH), entered into an Agreement and Plan of Merger with Schoeneman Beauty Supply, the shareholders of Schoeneman and F. Dale Schoeneman, as shareholder representative, pursuant to which Schoeneman merged into a wholly-owned acquisition subsidiary of the C...

Best of the Web SAC Bets On Former Employee’s RWC Fund The Real Reasons Behind Fed Secrecy BofA (NYSE: BAC) Board Weighs ‘Short-Term’ CEO High-Frequency Gain: Citadel Unit’s $1 Billion Despite Resignation, Ken Lewis Still Faces Legal And Political Woes Letterman reveals $2M extortion plot For Sale, Cheap: ‘Old GM’ P...

EnteroMedics Inc. (NASDAQ: ETRM) 72.3% LOWER; announced preliminary results from its EMPOWER Study. Based on an initial analysis, the study did not meet its primary and secondary efficacy endpoints. There were no therapy-related serious adverse events reported in the study. The EMPOWER Study is a randomized, double-blind, placebo-controlled pivotal...

Telik, Inc. (Nasdaq: TELK) 16.2% HIGHER; announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 200...

The FTSE Eurofirst 300 declined 2.1 per cent over the week after recording three straight days of losses ...